Dataset Information


Pharmacokinetics, Safety and Cognitive Function Profile of Rupatadine 10, 20 and 40 mg in Healthy Japanese Subjects: A Randomised Placebo-Controlled Trial.



Rupatadine is a marketed second generation antihistamine, with anti-PAF activity, indicated for symptomatic treatment of allergic rhinitis and urticaria. This study was conducted to evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of rupatadine in healthy Japanese subjects after single and multiple oral doses.


In this randomised, double-blind, placebo-controlled study, 27 male and female healthy Japanese subjects were administered single and multiple escalating rupatadine dose of 10, 20 and 40 mg or placebo. Blood samples were collected at different time points for PK measurements and subjects were assessed for safety and tolerability. The effect of rupatadine on cognitive functioning was evaluated by means of computerized cognitive tests: rapid visual information processing (RVP), reaction time (RT), spatial working memory (SWM) and visual analogue scales (VAS).


Exposure to rupatadine as measured by Cmax and AUC was found to increase in a dose dependent manner over the dose range of 10-40 mg for both single and multiple dose administration. The safety assessments showed that all treatment related side effects were of mild intensity and there were no serious adverse events (SAEs) or withdrawals due to treatment-emergent adverse events (TEAEs) in this study. The therapeutic dose of rupatadine did not show any CNS impairment in any of the cognitive tests.


This study demonstrated that rupatadine is safe and well tolerated by Japanese healthy subjects. The PK-PD profile confirmed previous experience with rupatadine.


PROVIDER: S-EPMC5025135 | BioStudies | 2016-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6567265 | BioStudies
2018-01-01 | S-EPMC5903252 | BioStudies
2021-01-01 | S-EPMC7818492 | BioStudies
2013-01-01 | S-EPMC3711902 | BioStudies
2015-01-01 | S-EPMC4674450 | BioStudies
1000-01-01 | S-EPMC6199364 | BioStudies
| S-EPMC5832788 | BioStudies
2021-01-01 | S-EPMC7861022 | BioStudies
2013-01-01 | S-EPMC4937663 | BioStudies
2020-01-01 | S-EPMC6994455 | BioStudies